Role of Dopamine Receptors in the Anticancer Activity of ONC201

C. Leah B. Kline, Marie D. Ralff, Amriti R. Lulla, +5

Neoplasia

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212

Jessica Wagner, C. Leah B. Kline, Marie D. Ralff, +11

Cell Cycle

Chemoprevention StrategyImipridone FamilyTumor BiologyPotent Anti-cancer EffectsAdditional Imipridones +15

Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation

Varun V. Prabhu, Bo Hong, Joshua E. Allen, +4

Cancer Research

OncologyC-jun-mediated δNp73 InhibitionMedicineStem CellsTumor Suppressor P53 +13

miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells

Amriti R. Lulla, Michael Slifker, Yan Zhou, +4

Cancer Research

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

Varun V. Prabhu, Mala K. Talekar, Amriti R. Lulla, +16

Cell Cycle

ImmunologyPathologyHematological MalignanciesImipridone ClassTumor Biology +17

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy

Elizabeth E. Miller, Hee Jin Lee, Amriti R. Lulla, +2

F1000Research

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

Avital Lev, Amriti R. Lulla, Jessica Wagner, +9

Oncotarget

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors

Varun V. Prabhu, Amriti R. Lulla, Neel S. Madhukar, +13

PLoS ONE

Potential BiomarkerCancer BiologyTumor BiologyCsc MarkersCancer Cell Biology +16

ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer

Avital Lev, Amriti R. Lulla, Brian C. Ross, +4

Molecular Cancer Research

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9

Xiaobing Tian, Nagib Ahsan, Amriti R. Lulla, +5

Neoplasia